

Supporting Information

Novel HIV-1 Capsid-Targeting Small Molecules of the PF74

Binding Site

Lei Wang^{a, §}, *Mary C. Casey*^b, *Sanjeev Kumar V. Vernekar*^a, *Rajkumar Lalji Sahani*^a, *Jayakanth Kankanala*^a, *Karen A. Kirby*^c, *Haijuan Du*^c, *Atsuko Hachiya*^d, *Huanchun Zhang*^c, *Philip R. Tedbury*^c, *Jiashu Xie*^a, *Stefan G. Sarafianos*^c, and *Zhengqiang Wang*^{*, a}

a Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA

b Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Christopher S. Bond Life Sciences Center, Columbia, MO 65211, USA

c Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA


d Clinical Research Center, Nagoya Medical Center, National Hospital Organization, Nagoya, Aichi 460-0001, Japan

§ Present address: Department of Pharmacy, School of Chemical Engineering, Dalian University of Technology, Dalian 116024, China

Table of Contents


Synthesis of intermediates	S2 – S4
NMR spectra	S5 – S58

Synthesis of intermediates




Reagents and conditions: (a) amine, HATU (or T₃P), DIPEA, DMF, rt, 12 h; (b) TFA; DCM, rt, 4-6 h; (c) HATU, DIPEA, DMF, rt, 12 h.

Synthesis of 59: To a solution of commercially available (*tert*-butoxycarbonyl)-*L*-phenylalanine (1.0 g, 3.8 mmol, 1 equiv.) in DMF (5 mL), HATU or T₃P (2 equiv.) and DIPEA (2 equiv.) were added and the mixture was stirred at room temperature for 20 min before amine (1.5 equiv.) was added. The mixture was further stirred at room temperature overnight. Upon completion, H₂O was added and the reaction mixture was extracted with EtOAc (3x50 mL). The organic phases were combined and washed with brine, dried over anhydrous MgSO₄, filtered and concentrated. The product was purified by Combi-flash on silica gel using EtOAc/hexane (1:4 to 2:1) as eluent.




Yield 68-89%. $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.39 – 7.29 (m, 3H), 7.20 – 7.19 (m, 3H), 6.94 – 6.80 (m, 4H), 5.17 (d, $J = 9.0$ Hz, 1H), 4.53 (q, $J = 7.5, 6.8$ Hz, 1H), 3.21 (s, 3H), 2.87 (dd, $J = 13.2, 7.4$ Hz, 1H), 2.69 (dd, $J = 13.0, 6.8$ Hz, 1H), 1.38 (s, 9H).


Synthesis of 60: TFA (5 equiv.) was added dropwise to a solution of **59** (1 equiv.) in DCM (5 mL) and the mixture was stirred at room temperature for 4-6 h. The solvent was evaporated to give the product as a TFA salt.




$^1\text{H NMR}$ (600 MHz, $\text{DMSO}-d_6$) δ 7.36 – 7.31 (m, 3H), 7.20 – 7.14 (m, 3H), 6.96 – 6.90 (m, 2H), 6.83 (d, $J = 8.2$ Hz, 2H), 3.30 (t, $J = 6.8$ Hz, 1H), 3.06 (s, 3H), 2.71 (dd, $J = 12.7, 6.8$ Hz, 1H), 2.43 (dd, $J = 13.2, 7.8$ Hz, 1H).




$^1\text{H NMR}$ (600 MHz, $\text{DMSO}-d_6$) δ 7.20 – 7.12 (m, 5H), 6.86 – 6.80 (m, 4H), 3.33 – 3.30 (m, 1H), 3.02 (s, 3H), 2.71 (dd, $J = 13.1, 7.3$ Hz, 1H), 2.44 (dd, $J = 12.8, 6.8$ Hz, 1H), 2.28 (s, 3H).




^1H NMR (600 MHz, CDCl_3) δ 7.32 – 7.27 (m, 4H), 6.98 – 6.93 (m, 5H), 4.09 – 4.06 (m, 1H), 3.12 (s, 3H), 3.05 – 3.04 (m, 2H).




^1H NMR (600 MHz, CDCl_3) δ 7.32 – 7.22 (m, 5H), 7.00 – 6.97 (m, 4H), 4.17 – 4.14 (m, 1H), 3.11 (s, 3H), 3.10 – 3.03 (m, 2H).



^1H NMR (600 MHz, CDCl_3) δ 7.37 – 7.20 (m, 6H), 6.98 – 6.97 (m, 3H), 4.12 – 4.10 (m, 1H), 3.10 (s, 3H), 3.08 – 3.02 (m, 2H).



^1H NMR (600 MHz, CDCl_3) δ 7.37 – 7.21 (m, 7H), 6.98 – 6.97 (m, 2H), 4.15 – 4.12 (m, 1H), 3.12 (s, 3H), 3.10 – 3.03 (m, 2H).



^1H NMR (600 MHz, CDCl_3) δ 7.31 – 7.23 (m, 8H), 6.97 – 6.96 (m, 2H), 4.03 – 4.00 (m, 1H), 3.76 – 3.72 (m, 1H), 3.48 – 3.43 (m, 1H), 3.08 – 3.01 (m, 2H), 1.00 (t, $J = 7.2$ Hz, 3H).

NMR spectra

